ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
The first report of ceroid lipofuscinosis type 11 in China: a novel mutation of GRN and updated clinical review.
Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ceroid lipofuscinosis type 11 (CLN11) is an extremely rare inherited neurodegenerative disorder, with only 29 cases reported worldwide to date. Additional case reports are urgently needed to further elucidate the clinical and epidemiological characteristics of this disease. In this study, we report the first documented case of CLN11 in China, which also represents the first globally reported case associated with a novel mutation involving complete deletion of exon 1 in the GRN gene. Moreover, we provide a comprehensive review of the clinical and subclinical features, management strategies, and outcomes of all reported CLN11 cases. For the first time, we propose a simplified clinical scoring system for CLN11 to assess disease severity. Our study may advance current understanding of GRN-related neurodegenerative disorders and expand the phenotypic and genotypic landscape of CLN11.
Indexed as
Identifiers
41021155What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.